Extracurriculars

3 TMCx companies have raised funds while completing the Houston accelerator

Three companies in TMCx's current cohort are leaving the program with new funds. Courtesy of TMCx

The Texas Medical Center's accelerator program is wrapping up its Digital Health cohort this week with the culmination of its TMCx Demo Day, and, while all of the companies have something to celebrate, three have announced that they are leaving the program with fresh funds.

Meru, Roundtrip, and Sani Nudge have raised over $10 million between the three companies. All three will be presenting at the TMCx Digital Health Demo Day on June 6 with the 16 other companies in the cohort. Click here to RSVP.

Three more TMCx companies have raised funds throughout the program but have let to formally announce their raises. Axem Neurotechnology, Optellum, and Dosentrx have collectively raised over $5 million this spring, according to TMCx.

Here's what you need to know about the three companies that have freshly padded pockets to grow their presence within the digital health industry.

Meru

Meru allows patients mental health treatment at their fingertips.Photos via meruhealth.com

Having access to health care has been an increasing issue and more and more startups are hoping they can provide solutions. Palo Alto, California-based Meru has created a low-cost digital clinic that offers an app-based treatment program from licensed therapists. The company completed a $4.2M raise in April 2019. The round was led by San Francisco-based Freestyle Capital.

Roundtrip

Philadelphia-based RoundTrip, which is in TMCx's current cohort, closed a hefty Series A round. Photo via roundtriphealth.com

An estimated 3.6 million patients miss or postpone their medical appointments annually, which leads to bigger medical issues that could have been prevented or treated earlier. Philadelphia-based RoundTrip created a platform where patients can book transportation to and from appointments. The startup closed its Series A round of $5.14 million led by Virginia-based Motley Fool Ventures in April.

Sani Nudge

Sani Nudge has optimized tech for sanitation compliance in hospitals. Photo via saninudge.com

Denmark-based Sani Nudge is one of the cohort's international members. The company's founders created a few devices that fit onto existing hospital gadgets — ID cards and hand sanitizing stations, for instance — that are able to track and monitor sanitization practices within hospitals.

According to the CDC, there are an estimated 680,000 health care-related infections in the U.S annually with a mortality rate of 10 percent.With the company's devices, hospitals can track compliance and hand sanitizing data within the hospital — but the health care professionals remain anonymous.

Sani Nudge raised $1.2 million in a round led by InQvation. The company will use the funds to grow its presence in the United States, specifically in Houston's medical center.

"Being part of the TMCx accelerator program has been game-changing," says CEO Theis Jensen in a release. "By attending a variety of workshops and hands-on events as well as receiving guidance from many experts and advisors have helped us to fully understand the US market, refine our strategies and connected us with hospitals so we can conduct studies in the TMC Medical Center".

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News